Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of fibrin clots through competitive inhibition of plasminogen activation to plasmin, thereby reducing plasmin-mediated fibrinolysis; additional technical details include the chemical name trans-4-(aminomethyl)cyclohexanecarboxylic acid, molecular formula C8H15NO2, molecular weight 157.21 g/mol, high oral bioavailability, primary renal excretion of unchanged drug, a pKa near 4.2, and common clinical oral dosing for acute heavy menstrual bleeding of 1 gram three times daily during menses for up to 3 to 5 days as tolerated under medical supervision.
Parent: Tranexamic acid
Parent: Tranexamic acid
Parent: Tranexamic Acid
Parent: Tranexamic Acid
Parent: Tranexamic acid
Typical pharmaceutical quality-control specifications define assay and related-substance limits to ensure safety and efficacy; a representative specification would report assay by validated chromatographic method at 98.5 to 101.5 percent on a dry basis, individual related substances not more than 0.20 percent, total related substances not more than 0.50 percent, with specific known related compounds and typical acceptance limits such as N-acetyl tranexamic acid not more than 0.10 percent, trans-4-(aminomethyl)cyclohexanecarboxylic acid positional isomers and stereochemical isomers individually not more than 0.05 to 0.20 percent, and trace levels of oligomeric or dimeric byproducts generally limited to 0.05 percent or less; additional routine controls include limits for residual solvents in accordance with international guidance, heavy metals commonly controlled to parts per million levels, and tests for loss on drying and inorganic residues to confirm material quality.
Tranexamic acid is primarily used to reduce excessive bleeding by stabilizing formed blood clots; clinically it is indicated for treatment of heavy menstrual bleeding and is also used in various settings to reduce surgical or traumatic bleeding under appropriate medical supervision.
Topical or oral use of tranexamic acid has been investigated for reducing hyperpigmentation and melasma because of its ability to inhibit plasmin-mediated pathways that can increase melanogenesis; evidence supports benefit for some patients when used topically or orally in controlled regimens, but use for skin conditions should follow dermatologist guidance due to variation in formulation, dosing, and possible adverse effects.
Tranexamic acid competitively inhibits the lysine binding sites on plasminogen, preventing its conversion to plasmin and reducing plasmin binding to fibrin; this decreases fibrinolysis, stabilizes fibrin clots, and thereby reduces ongoing bleeding.
Tranexamic acid is contraindicated in patients with active intravascular clotting, a history of thromboembolic disorders in whom risk outweighs benefit, known hypersensitivity to the drug, and in women with subarachnoid hemorrhage unless specifically indicated; caution is required in patients with severe renal impairment, history of thromboembolic disease, or concurrent use of hormonal contraceptives or procoagulant agents, and it is not indicated before the onset of menstruation in premenarcheal individuals.
